FLT3 and acute myeloid leukemia: The randomized, placebo-controlled, double-blind SORMAIN trial showed that up to ~2 years of post-transplantation sorafenib therapy in patients with FLT3-ITD–positive AML significantly reduced the risk of post-transplantation relapse or death compared with placebo (HR for relapse or death, .39; 95% CI, .18 to .85; P = .013) [7].